While the entire planet was on pause, or at least in slow motion, during the all too drawn-out period of the pandemic, the life sciences sector was in a flurry of activity.
Read More
As a McGill University spinout company, we at Molecular Forecaster are thrilled to support the recent landmark government investment into our alma mater through “DNA to RNA: An Inclusive Canadian Approach to Genomic-based RNA Therapeutics (D2R)”. The $165M investment, bolstered by another $185M+ commitment from academic and industrial partners will go towards supporting fundamental RNA research, including drug discovery efforts, which aligns perfectly with our company's mission and values.
Read More
A CRO, or contract research organization, is a company that provides, on a contractual basis, services in the biomedical research field. Given their crucial role in the development of new treatments and technologies, as well as their economic importance, BIOQuébec and CATALIS, with financial support from the Ministry of Economy and Innovation, conducted a study of Quebec CROs to chart the sector’s impact and measure its growth, strengths, and needs.
Read More
Bausch Health Companies Inc. (NYSE: BHC) (TSX: BHC) is pleased to announce the availability across Canada of its new prescription treatment RYALTRIS® (olopatadine hydrochloride and mometasone furoate nasal spray).
RYALTRIS has been approved by Health Canada for the symptomatic treatment of moderate to severe seasonal allergic rhinitis (SAR) and associated ocular symptoms in adults, adolescents, and children aged 6 years and older.
Read More
As part of the Effervescence conference, the Centre Québécois d'Innovation en Biotechnologie (CQIB) announced a contribution of $420,000 to seven startups for the clinical data validation of new medical technologies.
Read More
McGill is the recipient of a landmark $165 million CFREF grant to launch DNA to RNA: An Inclusive Canadian Approach to Genomic-based RNA Therapeutics (D2R), a first-of-its-kind global research effort specializing in the development and delivery of more inclusive genomic-based RNA therapeutics. D2R will receive significant support from more than 50 partners, including many from academia and industry, who have all pledged to invest in the research, which brings the total amount invested in D2R to $353 million.
Read More
Pharma in silica inc. announces today the closing of a $ 2,000,000 funding to continue the development of OpPacli™, an original nanomedicine developed to provide patients suffering from certain solid cancers with a well-tolerated and more efficient chemotherapy.
Read More
We are thrilled to welcome a new director to the board of directors of Immune Biosolutions Inc: Mr. Nicholas Franco. The arrival of Mr. Franco is part of the company’s development strategy. With over 32 years of experience in the pharmaceutical industry, research, marketing, sales, and business development in several therapeutic areas, both domestically and internationally, “He will certainly bring a unique strategic perspective of the industry and a vision focused on value creation to the Board,” says Luc Paquet, CEO of the company.
Read More
adMare BioInnovations is pleased to announce it has achieved LEED® v4 certification for the conception and construction of Building 2 at the Montreal Innovation Centre. LEED (Leadership in Energy and Environmental Design) was developed by the U.S. Green Building Council (USGBC) and is administered in Canada by the Canada Green Building Council (CAGBC). LEED is the most widely used green building rating system in the world and an international symbol of excellence. Through design, construction, and operation practices that improve environmental and human health, LEED-certified buildings are helping to make the world more sustainable.
Read More
CQDM is proud to announce the funding of a project worth $503,779 aiming at optimizing a new drug delivery platform in the lungs to treat several disabling pathologies such as chronic pulmonary obstruction and cystic fibrosis. CQDM is providing a grant of $201,512, made possible by the Ministère de l’Économie et de l’Innovation et de l’Énergie (MEIE). This funding, combined with the support of the Quebec company Feldan Therapeutics and the biotech company Amgen, will support the development of new therapeutic options. This project is part of a larger collaboration between the two companies, worth $1,427,757, to expand the potential of Feldan’s unique drug delivery technology.
Read More
The Ontario government is investing $7.5 million to help build a state-of-the-art Innovation Arena at the University of Waterloo. The new $35 million facility will be a hub for innovation in Ontario’s life sciences sector in Kitchener and Waterloo, supporting the development of new health technology and the commercialization of intellectual property and encouraging investment and job creation.
Read More
A new made-in-B.C. Life Sciences and Biomanufacturing Strategy outlines how the Province will capitalize on the industry value chain from discovery through to clinical trials and manufacturing by supporting targeted investments in people and infrastructure. To help grow innovative local companies, the Province is investing $10 million in a new wet lab facility with adMare Bioinnovations.
Read More
Laval, Canada – (BUSINESSWIRE) – April 13, 2023 – BIOQuébec, CQDM, Fonds de solidarité FTQ and adMare BioInnovations, co-organizers of Sweet Biopharma Day, are pleased to announce that Epitopea, represented by Steven Klein, is the winner of the 2023 edition.
Read More
Laval, April 13, 2023 – BIOQuébec’s board of directors is proud to announce that Benoit Larose has been named its executive director, effective May 1, 2023.
Read More
The adMare Academy is proud to launch the BioInnovation Scientist (BIS) Program: Foundations. This online, cohort-based program will provide early-career scientists with fundamental knowledge in therapeutics development while simultaneously building their professional skills to succeed in the Canadian life sciences industry.
Read More
As a leading full-service analytical laboratory serving the pharmaceutical industry for more than 30 years, at Neopharm, we are investing in the development of a new facility with state-of-the-art technology to support the growing field of biological products in the healthcare industry.
Read More
EVAH Corp. (EVAH or the company) has announced the successful completion of a Series B financing round, raising $8.5 million. This additional financing brings EVAH’s total funding since its launch in 2020 to $28.5 million.
A business and development platform in the animal health industry, EVAH specializes in the development of vaccines to prevent bacterial diseases in food animals. The company also designs microbiome solutions for improved growth performance and medicated feed against parasites.
Read More
In Canada, one out of twelve people—many of whom are children—has a rare disease. Unfortunately, treatments are only available for a small percentage of these conditions. Even when treatments that might dramatically improve the quality of a patient's life are available, they are often unaffordable and out of reach.
Today, the Honourable Jean-Yves Duclos, Minister of Health, announced measures in support of the first-ever National Strategy for Drugs for Rare Diseases, with an investment of up to $1.5 billion over three years. Through this, we will help increase access to, and affordability of, effective drugs for rare diseases to improve the health of patients across Canada, including children.
Read More
The Government of Canada continues to make significant investments to strengthen Canada’s biomanufacturing and life sciences sector. Our approach prioritizes innovative solutions and long-term domestic biomanufacturing capacity right here at home. Since March 2020, over $1.8 billion has been invested across 34 projects to rebuild Canada’s vaccines, therapeutics and biomanufacturing capacity.
Read More
Diex Research announces the official opening of its Quebec City site since its relocation on September 12, 2022, which is now located at Place de la Cité. Diex Research is a leader in the clinical research industry and is committed to providing superior services to its clients while maintaining the highest standards for safety and ethics.
Read More